schliessen

Filtern

 

Bibliotheken

The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet’s disease: indication of anti-TNFα monoclonal antibodies

Background Clinical evidence regarding intestinal Behçet’s disease (BD) management is lacking and intestinal lesions are a poor prognostic factor. In 2007, the Japan consensus statement for diagnosis and management of intestinal BD was developed. Recently, the efficacy of anti-tumor necrosis factor... Full description

Journal Title: Journal of Gastroenterology 2013-08-18, Vol.49 (1), p.156-162
Main Author: Hisamatsu, Tadakazu
Other Authors: Ueno, Fumiaki , Matsumoto, Takayuki , Kobayashi, Kiyonori , Koganei, Kazutaka , Kunisaki, Reiko , Hirai, Fumihito , Nagahori, Masakazu , Matsushita, Mitsunobu , Kobayashi, Kenji , Kishimoto, Mitsumasa , Takeno, Mitsuhiro , Tanaka, Masanori , Inoue, Nagamu , Hibi, Toshifumi
Format: Electronic Article Electronic Article
Language: English
Subjects:
Publisher: Tokyo: Springer Japan
ID: ISSN: 0944-1174
Link: https://www.ncbi.nlm.nih.gov/pubmed/23955155
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_1490900372
title: The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet’s disease: indication of anti-TNFα monoclonal antibodies
format: Article
creator:
  • Hisamatsu, Tadakazu
  • Ueno, Fumiaki
  • Matsumoto, Takayuki
  • Kobayashi, Kiyonori
  • Koganei, Kazutaka
  • Kunisaki, Reiko
  • Hirai, Fumihito
  • Nagahori, Masakazu
  • Matsushita, Mitsunobu
  • Kobayashi, Kenji
  • Kishimoto, Mitsumasa
  • Takeno, Mitsuhiro
  • Tanaka, Masanori
  • Inoue, Nagamu
  • Hibi, Toshifumi
subjects:
  • Abdominal Surgery
  • Anti
  • Anti-TNFα mAb
  • Antibodies, Monoclonal - therapeutic use
  • Behcet Syndrome - diagnosis
  • Behcet Syndrome - drug therapy
  • Colorectal Surgery
  • Consensus statements
  • Delphi Technique
  • Gastroenterology
  • Gastrointestinal Agents - therapeutic use
  • Hepatology
  • Humans
  • Intestinal Behçet’s disease
  • Intestinal Diseases - diagnosis
  • Intestinal Diseases - drug therapy
  • Medicine
  • Medicine & Public Health
  • Practice Guidelines as Topic
  • Rapid Communication
  • Surgical Oncology
  • TNFα mAb
  • Tumor Necrosis Factor-alpha - antagonists & inhibitors
ispartof: Journal of Gastroenterology, 2013-08-18, Vol.49 (1), p.156-162
description: Background Clinical evidence regarding intestinal Behçet’s disease (BD) management is lacking and intestinal lesions are a poor prognostic factor. In 2007, the Japan consensus statement for diagnosis and management of intestinal BD was developed. Recently, the efficacy of anti-tumor necrosis factor (TNF)α monoclonal antibodies (mAbs), and infliximab (IFX) was reported and adalimumab (ADA) was approved for intestinal BD in Japan. This study renewed consensus-based practice guidelines for diagnosis and treatment of intestinal BD focusing on the indication of anti-TNFα mAbs. Methods An expert panel of Japanese gastroenterology and rheumatology specialists was involved. Clinical statements for ratings were extracted from the literature, a professional group survey, and by an expert panel discussion, which rated clinical statements on a nine-point scale. After the first round of ratings, a panelist meeting discussed areas of disagreement and clarified areas of uncertainty. The list of clinical statements was revised after the panelist meeting and a second round of ratings was conducted. Results Fifteen relevant articles were selected. Based on the first edition consensus statement, improved clinical statements regarding indications for anti-TNFα mAbs use were developed. After a two-round modified Delphi approach, the second edition of consensus statements was finalized. Conclusions In addition to standard therapies in the first edition, anti-TNFα mAbs (ADA and IFX) should be considered as a standard therapy for intestinal BD. Colchicines, thalidomide, other pharmacological therapy, endoscopic therapy, and leukocytapheresis were deemed experimental therapies.
language: eng
source:
identifier: ISSN: 0944-1174
fulltext: no_fulltext
issn:
  • 0944-1174
  • 1435-5922
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.597874
LOCALfalse
PrimoNMBib
record
control
sourceidproquest_pubme
recordidTN_cdi_proquest_miscellaneous_1490900372
sourceformatXML
sourcesystemPC
sourcerecordid1490900372
originalsourceidFETCH-LOGICAL-1541t-c3b3e9f3a7e4ff33ca5c517b00c9fa02c517f91ec22ac2ae07c8098e6492b7d90
addsrcrecordideNp9kr9uFDEQxlcIRI7AA9CgLWkW_Dd7pkCCKAGkKDRHbXnt8Z2jXfvY8QbR8RrhBah5BnoegifBm0siQpHK8sz3-8bjmap6SskLSkj7EgmRXDaE8oYsW9aIe9WCihKRirH71YIoIRpKW7FXPUI8I0VI5PJhtce4kpJKuai-rzZQs-hqcCGHFOvka5siQsQJa8wmwwAxY-3TWOeidcGsY8KAtSnUYKJZXypmMMQMmEM0ff0WNr9-QP7z7QILgmAQXpW8C9ZclzExh2Z1evz7Zz2kmGyfZnCOdskFwMfVA296hCdX53716fhodfi-Ofn47sPhm5OGSkFzY3nHQXluWhDec26NtJK2HSFWeUPYfPGKgmXMWGaAtHZJ1BIOhGJd6xTZr17vfLdTN4CzpZnR9Ho7hsGMX3UyQd_OxLDR63Su-VJJqmQxON0ZpC1EE0a4xboIWTtw01Z_8brMQFvlrOeSSce8bYUnQhBDRcuksB0cuGL4_OpFY_o8lS_VQ0ALfW8ipAk1FYooQnjLipTupHZMiCP4m9qU6HlJ9G5JdJm9npdEi8I8-7fhG-J6K4qg_c_Uhnw5t9J_6O-0ZjsSi2lcw6jP0jSWueId0F_ezt9C
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid1490900372
display
typearticle
titleThe 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet’s disease: indication of anti-TNFα monoclonal antibodies
creatorHisamatsu, Tadakazu ; Ueno, Fumiaki ; Matsumoto, Takayuki ; Kobayashi, Kiyonori ; Koganei, Kazutaka ; Kunisaki, Reiko ; Hirai, Fumihito ; Nagahori, Masakazu ; Matsushita, Mitsunobu ; Kobayashi, Kenji ; Kishimoto, Mitsumasa ; Takeno, Mitsuhiro ; Tanaka, Masanori ; Inoue, Nagamu ; Hibi, Toshifumi
creatorcontribHisamatsu, Tadakazu ; Ueno, Fumiaki ; Matsumoto, Takayuki ; Kobayashi, Kiyonori ; Koganei, Kazutaka ; Kunisaki, Reiko ; Hirai, Fumihito ; Nagahori, Masakazu ; Matsushita, Mitsunobu ; Kobayashi, Kenji ; Kishimoto, Mitsumasa ; Takeno, Mitsuhiro ; Tanaka, Masanori ; Inoue, Nagamu ; Hibi, Toshifumi
descriptionBackground Clinical evidence regarding intestinal Behçet’s disease (BD) management is lacking and intestinal lesions are a poor prognostic factor. In 2007, the Japan consensus statement for diagnosis and management of intestinal BD was developed. Recently, the efficacy of anti-tumor necrosis factor (TNF)α monoclonal antibodies (mAbs), and infliximab (IFX) was reported and adalimumab (ADA) was approved for intestinal BD in Japan. This study renewed consensus-based practice guidelines for diagnosis and treatment of intestinal BD focusing on the indication of anti-TNFα mAbs. Methods An expert panel of Japanese gastroenterology and rheumatology specialists was involved. Clinical statements for ratings were extracted from the literature, a professional group survey, and by an expert panel discussion, which rated clinical statements on a nine-point scale. After the first round of ratings, a panelist meeting discussed areas of disagreement and clarified areas of uncertainty. The list of clinical statements was revised after the panelist meeting and a second round of ratings was conducted. Results Fifteen relevant articles were selected. Based on the first edition consensus statement, improved clinical statements regarding indications for anti-TNFα mAbs use were developed. After a two-round modified Delphi approach, the second edition of consensus statements was finalized. Conclusions In addition to standard therapies in the first edition, anti-TNFα mAbs (ADA and IFX) should be considered as a standard therapy for intestinal BD. Colchicines, thalidomide, other pharmacological therapy, endoscopic therapy, and leukocytapheresis were deemed experimental therapies.
identifier
0ISSN: 0944-1174
1EISSN: 1435-5922
2DOI: 10.1007/s00535-013-0872-4
3PMID: 23955155
languageeng
publisherTokyo: Springer Japan
subjectAbdominal Surgery ; Anti ; Anti-TNFα mAb ; Antibodies, Monoclonal - therapeutic use ; Behcet Syndrome - diagnosis ; Behcet Syndrome - drug therapy ; Colorectal Surgery ; Consensus statements ; Delphi Technique ; Gastroenterology ; Gastrointestinal Agents - therapeutic use ; Hepatology ; Humans ; Intestinal Behçet’s disease ; Intestinal Diseases - diagnosis ; Intestinal Diseases - drug therapy ; Medicine ; Medicine & Public Health ; Practice Guidelines as Topic ; Rapid Communication ; Surgical Oncology ; TNFα mAb ; Tumor Necrosis Factor-alpha - antagonists & inhibitors
ispartofJournal of Gastroenterology, 2013-08-18, Vol.49 (1), p.156-162
rightsThe Author(s) 2013
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-1541t-c3b3e9f3a7e4ff33ca5c517b00c9fa02c517f91ec22ac2ae07c8098e6492b7d90
citesFETCH-LOGICAL-1541t-c3b3e9f3a7e4ff33ca5c517b00c9fa02c517f91ec22ac2ae07c8098e6492b7d90
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23955155$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Hisamatsu, Tadakazu
1Ueno, Fumiaki
2Matsumoto, Takayuki
3Kobayashi, Kiyonori
4Koganei, Kazutaka
5Kunisaki, Reiko
6Hirai, Fumihito
7Nagahori, Masakazu
8Matsushita, Mitsunobu
9Kobayashi, Kenji
10Kishimoto, Mitsumasa
11Takeno, Mitsuhiro
12Tanaka, Masanori
13Inoue, Nagamu
14Hibi, Toshifumi
title
0The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet’s disease: indication of anti-TNFα monoclonal antibodies
1Journal of Gastroenterology
addtitle
0J Gastroenterol
1J Gastroenterol
descriptionBackground Clinical evidence regarding intestinal Behçet’s disease (BD) management is lacking and intestinal lesions are a poor prognostic factor. In 2007, the Japan consensus statement for diagnosis and management of intestinal BD was developed. Recently, the efficacy of anti-tumor necrosis factor (TNF)α monoclonal antibodies (mAbs), and infliximab (IFX) was reported and adalimumab (ADA) was approved for intestinal BD in Japan. This study renewed consensus-based practice guidelines for diagnosis and treatment of intestinal BD focusing on the indication of anti-TNFα mAbs. Methods An expert panel of Japanese gastroenterology and rheumatology specialists was involved. Clinical statements for ratings were extracted from the literature, a professional group survey, and by an expert panel discussion, which rated clinical statements on a nine-point scale. After the first round of ratings, a panelist meeting discussed areas of disagreement and clarified areas of uncertainty. The list of clinical statements was revised after the panelist meeting and a second round of ratings was conducted. Results Fifteen relevant articles were selected. Based on the first edition consensus statement, improved clinical statements regarding indications for anti-TNFα mAbs use were developed. After a two-round modified Delphi approach, the second edition of consensus statements was finalized. Conclusions In addition to standard therapies in the first edition, anti-TNFα mAbs (ADA and IFX) should be considered as a standard therapy for intestinal BD. Colchicines, thalidomide, other pharmacological therapy, endoscopic therapy, and leukocytapheresis were deemed experimental therapies.
subject
0Abdominal Surgery
1Anti
2Anti-TNFα mAb
3Antibodies, Monoclonal - therapeutic use
4Behcet Syndrome - diagnosis
5Behcet Syndrome - drug therapy
6Colorectal Surgery
7Consensus statements
8Delphi Technique
9Gastroenterology
10Gastrointestinal Agents - therapeutic use
11Hepatology
12Humans
13Intestinal Behçet’s disease
14Intestinal Diseases - diagnosis
15Intestinal Diseases - drug therapy
16Medicine
17Medicine & Public Health
18Practice Guidelines as Topic
19Rapid Communication
20Surgical Oncology
21TNFα mAb
22Tumor Necrosis Factor-alpha - antagonists & inhibitors
issn
00944-1174
11435-5922
fulltextfalse
rsrctypearticle
creationdate2013
recordtypearticle
recordideNp9kr9uFDEQxlcIRI7AA9CgLWkW_Dd7pkCCKAGkKDRHbXnt8Z2jXfvY8QbR8RrhBah5BnoegifBm0siQpHK8sz3-8bjmap6SskLSkj7EgmRXDaE8oYsW9aIe9WCihKRirH71YIoIRpKW7FXPUI8I0VI5PJhtce4kpJKuai-rzZQs-hqcCGHFOvka5siQsQJa8wmwwAxY-3TWOeidcGsY8KAtSnUYKJZXypmMMQMmEM0ff0WNr9-QP7z7QILgmAQXpW8C9ZclzExh2Z1evz7Zz2kmGyfZnCOdskFwMfVA296hCdX53716fhodfi-Ofn47sPhm5OGSkFzY3nHQXluWhDec26NtJK2HSFWeUPYfPGKgmXMWGaAtHZJ1BIOhGJd6xTZr17vfLdTN4CzpZnR9Ho7hsGMX3UyQd_OxLDR63Su-VJJqmQxON0ZpC1EE0a4xboIWTtw01Z_8brMQFvlrOeSSce8bYUnQhBDRcuksB0cuGL4_OpFY_o8lS_VQ0ALfW8ipAk1FYooQnjLipTupHZMiCP4m9qU6HlJ9G5JdJm9npdEi8I8-7fhG-J6K4qg_c_Uhnw5t9J_6O-0ZjsSi2lcw6jP0jSWueId0F_ezt9C
startdate20130818
enddate20130818
creator
0Hisamatsu, Tadakazu
1Ueno, Fumiaki
2Matsumoto, Takayuki
3Kobayashi, Kiyonori
4Koganei, Kazutaka
5Kunisaki, Reiko
6Hirai, Fumihito
7Nagahori, Masakazu
8Matsushita, Mitsunobu
9Kobayashi, Kenji
10Kishimoto, Mitsumasa
11Takeno, Mitsuhiro
12Tanaka, Masanori
13Inoue, Nagamu
14Hibi, Toshifumi
general
0Springer Japan
1Springer Nature
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
87X8
9BOBZL
10CLFQK
115PM
sort
creationdate20130818
titleThe 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet’s disease: indication of anti-TNFα monoclonal antibodies
authorHisamatsu, Tadakazu ; Ueno, Fumiaki ; Matsumoto, Takayuki ; Kobayashi, Kiyonori ; Koganei, Kazutaka ; Kunisaki, Reiko ; Hirai, Fumihito ; Nagahori, Masakazu ; Matsushita, Mitsunobu ; Kobayashi, Kenji ; Kishimoto, Mitsumasa ; Takeno, Mitsuhiro ; Tanaka, Masanori ; Inoue, Nagamu ; Hibi, Toshifumi
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1541t-c3b3e9f3a7e4ff33ca5c517b00c9fa02c517f91ec22ac2ae07c8098e6492b7d90
rsrctypearticles
prefilterarticles
languageeng
creationdate2013
topic
0Abdominal Surgery
1Anti
2Anti-TNFα mAb
3Antibodies, Monoclonal - therapeutic use
4Behcet Syndrome - diagnosis
5Behcet Syndrome - drug therapy
6Colorectal Surgery
7Consensus statements
8Delphi Technique
9Gastroenterology
10Gastrointestinal Agents - therapeutic use
11Hepatology
12Humans
13Intestinal Behçet’s disease
14Intestinal Diseases - diagnosis
15Intestinal Diseases - drug therapy
16Medicine
17Medicine & Public Health
18Practice Guidelines as Topic
19Rapid Communication
20Surgical Oncology
21TNFα mAb
22Tumor Necrosis Factor-alpha - antagonists & inhibitors
toplevelpeer_reviewed
creatorcontrib
0Hisamatsu, Tadakazu
1Ueno, Fumiaki
2Matsumoto, Takayuki
3Kobayashi, Kiyonori
4Koganei, Kazutaka
5Kunisaki, Reiko
6Hirai, Fumihito
7Nagahori, Masakazu
8Matsushita, Mitsunobu
9Kobayashi, Kenji
10Kishimoto, Mitsumasa
11Takeno, Mitsuhiro
12Tanaka, Masanori
13Inoue, Nagamu
14Hibi, Toshifumi
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7MEDLINE - Academic
8OpenAIRE (Open Access)
9OpenAIRE
10PubMed Central (Full Participant titles)
jtitleJournal of Gastroenterology
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Hisamatsu, Tadakazu
1Ueno, Fumiaki
2Matsumoto, Takayuki
3Kobayashi, Kiyonori
4Koganei, Kazutaka
5Kunisaki, Reiko
6Hirai, Fumihito
7Nagahori, Masakazu
8Matsushita, Mitsunobu
9Kobayashi, Kenji
10Kishimoto, Mitsumasa
11Takeno, Mitsuhiro
12Tanaka, Masanori
13Inoue, Nagamu
14Hibi, Toshifumi
formatjournal
genrearticle
ristypeJOUR
atitleThe 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet’s disease: indication of anti-TNFα monoclonal antibodies
jtitleJournal of Gastroenterology
stitleJ Gastroenterol
addtitleJ Gastroenterol
date2013-08-18
risdate2013
volume49
issue1
spage156
epage162
pages156-162
issn0944-1174
eissn1435-5922
abstractBackground Clinical evidence regarding intestinal Behçet’s disease (BD) management is lacking and intestinal lesions are a poor prognostic factor. In 2007, the Japan consensus statement for diagnosis and management of intestinal BD was developed. Recently, the efficacy of anti-tumor necrosis factor (TNF)α monoclonal antibodies (mAbs), and infliximab (IFX) was reported and adalimumab (ADA) was approved for intestinal BD in Japan. This study renewed consensus-based practice guidelines for diagnosis and treatment of intestinal BD focusing on the indication of anti-TNFα mAbs. Methods An expert panel of Japanese gastroenterology and rheumatology specialists was involved. Clinical statements for ratings were extracted from the literature, a professional group survey, and by an expert panel discussion, which rated clinical statements on a nine-point scale. After the first round of ratings, a panelist meeting discussed areas of disagreement and clarified areas of uncertainty. The list of clinical statements was revised after the panelist meeting and a second round of ratings was conducted. Results Fifteen relevant articles were selected. Based on the first edition consensus statement, improved clinical statements regarding indications for anti-TNFα mAbs use were developed. After a two-round modified Delphi approach, the second edition of consensus statements was finalized. Conclusions In addition to standard therapies in the first edition, anti-TNFα mAbs (ADA and IFX) should be considered as a standard therapy for intestinal BD. Colchicines, thalidomide, other pharmacological therapy, endoscopic therapy, and leukocytapheresis were deemed experimental therapies.
copTokyo
pubSpringer Japan
pmid23955155
doi10.1007/s00535-013-0872-4
oafree_for_read